Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genfit SA ( (GNFT) ) has shared an update.
On September 22, 2025, GENFIT announced its first-half 2025 financial results, highlighting a cash position of €107.5 million as of June 30, 2025, and significant revenue from milestone payments related to its drug Iqirvo® (elafibranor) in Europe. The company decided to discontinue its VS-01 program for ACLF due to safety concerns but remains committed to other ACLF-related programs and continues to explore new therapeutic avenues. The withdrawal of a key competitor from the U.S. market is expected to benefit Iqirvo® sales. GENFIT’s strategic moves, including the acquisition of full rights for GNS561 and a royalty financing agreement, have extended its cash runway beyond 2028, providing financial stability and opportunities for further development initiatives.
The most recent analyst rating on (GNFT) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s overall stock score reflects a strong financial recovery with significant revenue growth and improved cash flow. The technical indicators are positive, supporting a favorable short-term outlook. However, the high P/E ratio suggests potential overvaluation, which is a significant risk factor. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT S.A. is a late-stage biopharmaceutical company focused on developing therapies for rare and life-threatening liver diseases. The company is involved in various programs targeting conditions such as Acute on-Chronic Liver Failure (ACLF) and Primary Biliary Cholangitis (PBC), with a strong emphasis on innovative therapeutic options.
Average Trading Volume: 3,452
Technical Sentiment Signal: Buy
Current Market Cap: $211.6M
For a thorough assessment of GNFT stock, go to TipRanks’ Stock Analysis page.